Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers... Show more
Verrica Pharmaceuticals Inc. (VRCA) is a U.S.-based dermatology therapeutics company focused on identifying, developing, and commercializing treatments for skin conditions that have historically had few approved therapies. Investors follow the company primarily because of its first-to-market position in molluscum contagiosum and its pipeline aimed at larger dermatology indications such as common warts and non-melanoma skin cancers. This company overview explains how Verrica operates, where its revenue comes from, and the factors that shape its market position.
Verrica was founded in 2013 and is headquartered in West Chester, Pennsylvania. The company became publicly traded on the Nasdaq Capital Market in June 2018. Verrica's business model centers on commercializing its approved product while advancing a clinical pipeline in medical and oncologic dermatology.
The company's flagship product, YCANTH (formerly VP-102), is a proprietary drug-device combination containing a controlled formulation of cantharidin, a naturally sourced blistering agent long used in dermatology. Delivered through a single-use precision applicator, YCANTH became the first and only healthcare professional-administered product approved by the FDA to treat molluscum contagiosum, a highly contagious viral skin infection affecting an estimated six million people in the United States, primarily children. The company is also developing YCANTH as a potential treatment for common warts, a condition it estimates affects more than 22 million people in the U.S.
Beyond YCANTH, Verrica is developing VP-315 (ruxotemitide), a first-in-class oncolytic peptide administered directly into tumors to induce immunogenic cell death. Licensed from Lytix Biopharma, VP-315 is being developed for dermatologic oncology indications, with an initial focus on basal cell carcinoma and squamous cell carcinoma.
Verrica's primary revenue source is U.S. net product sales of YCANTH, supplemented by license and collaboration revenue tied to its partnership with Torii Pharmaceutical Co., Ltd., a subsidiary of Shionogi & Co., Ltd., for the development and commercialization of YCANTH in Japan. The company has also entered distribution agreements for additional international markets, such as an exclusive arrangement covering Israel.
Verrica attracts investor attention because of its first-mover position in an underserved area of dermatology. Before YCANTH's approval, molluscum contagiosum had no FDA-approved, physician-administered treatment, leaving many patients with a "watch and wait" approach. The company's commercial execution in building a prescriber base and expanding insurance access is a key part of its financial profile.
The pipeline is another important growth driver. A successful label expansion of YCANTH into common warts — a market the company describes as several times larger than molluscum — would meaningfully broaden its addressable opportunity. Similarly, VP-315 represents a potential entry into dermatologic oncology, a category with substantial unmet medical need for non-surgical treatment options. Strategic partnerships, including Torii's launch of YCANTH in Japan and Torii's funding of a large share of the common warts Phase 3 program, provide additional validation and help offset development costs.
Verrica operates with the risks common to clinical-stage and early-commercial biopharmaceutical companies. Its revenue remains concentrated in a single approved product, YCANTH, making the company sensitive to prescription trends, reimbursement decisions, and competitive dynamics. Rival therapies, including at-home treatment options, have entered the molluscum market, increasing competitive pressure.
The company also depends on successful clinical outcomes. The common warts Phase 3 program and the VP-315 oncology program may not achieve their endpoints or secure regulatory approval, and development timelines can shift. As a smaller company, Verrica has periodically raised capital through equity offerings and credit facilities to fund operations, which can dilute existing shareholders and reflects ongoing financing needs. Investors should also consider regulatory risk, reliance on third-party partners for international commercialization, and the inherent uncertainty of drug pricing and market access in U.S. healthcare.
Investors researching companies like Verrica can use Tickeron's AI Screener, an AI-powered stock and ETF discovery platform. The AI Screener helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. It enables users to efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. Explore the AI Screener to see how it can support your research process.
Verrica Pharmaceuticals occupies a distinctive position as a dermatology-focused biopharmaceutical company with an approved, first-in-class product and a pipeline targeting larger indications. Its combination of a commercialized asset, a global Phase 3 program, and an emerging oncology platform distinguishes it from earlier-stage peers, while its single-product revenue base and development-stage pipeline underscore the risks inherent in specialty pharma. For investors interested in medical dermatology and dermatologic oncology, Verrica remains a company worth understanding within the broader biopharmaceutical landscape.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a manufacturer of pharmaceutical products
Industry Biotechnology